

Manufacturer Name	NDC	Name of Prescription Drug
----------------------	-----	---------------------------

AvKare, Inc.	50268-0331-12	Flucytosine Oral Capsule 250 MG
--------------	---------------	---------------------------------

AvKare, Inc.	50268-0332-12	Flucytosine Oral Capsule 500 MG
--------------	---------------	---------------------------------

Strength	Pack Size/Volume	WAC (as of date of commercial availability)	Date of Commercial Availability	Estimated volume of patients who may be prescribed drug
250mg	20	\$1,631.77	5/10/2021	N/A
500mg	20	\$3,082.94	5/10/2021	N/A

Breakthrough therapy designation? (Y/N)	Priority Review? (Y/N)	Date and price of acquisition if the drug was not developed by the manufacturer else N/A	A description of the marketing and pricing plans used in the launch of the new drug
N	N	N/A	This drug is a generic drug and marketed in traditional generic ways through typical wholesale and chargeback channels.
N	N	N/A	This drug is a generic drug and marketed in traditional generic ways through typical wholesale and chargeback channels.